AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 DEC 11 - (NewsRx.com & NewsRx.net) -- Researchers in Australia have suggested what may be a practical way to obtain cells for studies of dendritic cell-based vaccines.
F.J. Radcliff and colleagues, Royal Children's Hospital, described their study methods: "The number of dendritic cells (DC) circulating in the peripheral blood of cancer patients were monitored at multiple time points during chemotherapy and granulocyte colony-stimulating factor (G-CSF) support. DC were identified via the lack of expression of standard lineage markers and high expression of HLA-DR (LN-/DR+). The expression of DC-associated markers, including CD83, CD11c, IL-3Ra (CDw123) and CD86, within this LN-/DR+ population was also monitored."
The researchers reported that "[m]aximal mobilization occurred during recovery on day 12, with a mean 32-fold increase in LN-/DR+ numbers. The most striking increase was observed in the LN-/DR+/CD83+ cell population: 12 days after commencement of treatment, the proportion of these cells had increased by approximately 120-fold when compared with baseline. Peripheral blood mononuclear cell (PBMC) and CD34+ cell numbers also peaked 12 days into the ...